학술논문
Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
Document Type
Article
Author
Source
Subject
*CLINICAL drug trials
*THERAPEUTICS
*SCIENTIFIC observation
*HOSPITAL emergency services
*INSULIN derivatives
*RETROSPECTIVE studies
*ACQUISITION of data
*TYPE 2 diabetes
*MEDICAL care use
*TREATMENT effectiveness
*RISK assessment
*HYPOGLYCEMIA
*PSYCHOSOCIAL factors
*MEDICAL records
*PATIENT compliance
*PEOPLE with diabetes
*DISEASE risk factors
*EVALUATION
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0891-8929
Abstract
People with type 2 diabetes receiving a second-generation basal insulin (BI) analog may be switched to a first-generation formulation for financial reasons or changes in health insurance. However, because second-generation BI analogs have more even pharmacokinetic profiles, longer durations of action (>24 vs. ≤24 hours), and more stable action profiles than first-generation BI analogs, such a change may result in suboptimal treatment persistence and/or adherence. This study compared treatment persistence, treatment adherence, rates of hypoglycemia, and health care resource utilization outcomes in people with type 2 diabetes who either continued treatment with the second-generation BI Gla-300 or switched to a first-generation BI. The study showed that continuing with Gla-300 was associated with a lower risk of discontinuing therapy, fewer emergency department visits, and lower hypoglycemia event rates than switching to a first-generation BI. [ABSTRACT FROM AUTHOR]